In 2006, the Legatum Foundation, a founding investor of the END Fund, funded NTD programs in Rwanda and Burundi. Over the span of four years, they treated more than eight million people for diseases like intestinal worms, schistosomiasis, and lymphatic filariasis at a small cost. Their intervention demonstrated the feasibility of quickly scaling up NTD programs to a national level. It helped generate the evidence and enthusiasm for creating the END Fund as a philanthropic platform to engage others in ending neglected diseases.
Since our founding in 2012, the END Fund has worked with our partners to provide more than a billion treatments.
